CMMB Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 11.91%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Chemomab Therapeutics Insider Trading History Chart

Chemomab Therapeutics Share Price & Price History

^$1.65

▲ +0.05 (3.13%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Chemomab Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/3/2023	Israel Gp Ltd. Orbimed	Major Shareholder	Sell	336,900	$3.58	$1,206,102.00	2,241,274
11/16/2022	George Adi Mor	Insider	Sell	324,775	$2.08	$675,532.00	324,775
11/16/2022	Neil Harris Cohen	Director	Sell	2,409	$2.00	$4,818.00	10,000
3/18/2022	Joel Michael Maryles	Director	Buy	1,000	$4.34	$4,340.00
3/16/2022	Donald Marvin	CFO	Buy	500	$3.27	$1,635.00	2,000
3/14/2022	Dale R Pfost	CEO	Buy	2,500	$3.98	$9,950.00
3/14/2022	Donald Marvin	CFO	Buy	1,250	$4.04	$5,050.00
3/14/2022	Neil Harris Cohen	Director	Buy	6,000	$4.35	$26,100.00
12/6/2021	Neil Harris Cohen	Director	Buy	2,000	$7.43	$14,860.00

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

SEC Filings (Institutional Ownership Changes) for Chemomab Therapeutics (NASDAQ:CMMB)

46.05% of Chemomab Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Chemomab Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2024	Sphera Funds Management LTD.	1,214,575	$1.91M	0.3%	N/A	8.458%
2/1/2023	Kestra Private Wealth Services LLC	31,241	$100K	0.0%	N/A	0.271%
2/14/2022	GSA Capital Partners LLP	11,277	$78K	0.0%	N/A	0.099%
1/28/2022	ARK Investment Management LLC	267,292	$1.84M	0.0%	+48.1%	2.344%
11/17/2021	Yahav Achim Ve Achayot Provident Funds Management Co Ltd.	3,097	$34K	0.0%	N/A	0.027%
11/5/2021	Advisor Group Holdings Inc.	54,821	$0.61M	0.0%	N/A	0.481%
11/3/2021	Meitav Dash Investments Ltd.	37,567	$0.42M	0.0%	-7.6%	0.330%
9/17/2021	Virtu Financial LLC	13,180	$0.25M	0.0%	N/A	0.116%
8/25/2021	Marshall Wace LLP	63,554	$1.21M	0.0%	N/A	0.558%
8/25/2021	Marshall Wace North America L.P.	44,035	$0.84M	0.0%	N/A	0.386%
8/18/2021	Ikarian Capital LLC	290,534	$5.53M	0.4%	N/A	2.640%
8/18/2021	Meitav Dash Investments Ltd.	40,664	$0.77M	0.0%	+389.3%	0.370%
8/17/2021	Boothbay Fund Management LLC	54,729	$1.04M	0.0%	-11.4%	0.512%
8/16/2021	Marshall Wace LLP	63,554	$1.21M	0.0%	N/A	0.594%
8/5/2021	Meitav Dash Investments Ltd.	40,664	$0.77M	0.0%	+389.3%	0.380%
5/18/2021	Orbimed Advisors LLC	2,578,174	$74.02M	0.7%	N/A	110.320%
5/13/2021	Renaissance Technologies LLC	7,023	$0.20M	0.0%	N/A	0.301%
5/6/2021	Meitav Dash Investments Ltd.	8,311	$0.24M	0.0%	N/A	0.356%

Data available starting January 2016

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Today's Range

Now: $1.65

$1.58

$1.68

50 Day Range

MA: $1.52

$1.13

$1.85

52 Week Range

Now: $1.65

$0.42

$2.55

Volume

42,387 shs

Average Volume

107,038 shs

Market Capitalization

$23.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.53

Who are the company insiders with the largest holdings of Chemomab Therapeutics?: Chemomab Therapeutics' top insider investors include:
Israel Gp Ltd Orbimed (Major Shareholder)
Learn More about top insider investors at Chemomab Therapeutics.
Who are the major institutional investors of Chemomab Therapeutics?: Chemomab Therapeutics' top institutional shareholders include:
Sphera Funds Management LTD. — 8.46%
Learn More about top institutional investors of Chemomab Therapeutics stock.
Which major investors are buying Chemomab Therapeutics stock?: Within the last quarter, CMMB stock was purchased by institutional investors including:
Sphera Funds Management LTD.